latest
Market/Novel Tech Articles

Allergan issues an urgent device recall for the XEN® Glaucoma Treatment System (XEN® 45 Gel Stent)

Allergan plc (NYSE: AGN) announced a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot were observed to have trace amounts of polishing compounds that are used in the needle sleeve manufacturing process, according to a joint news release with ASCRS.  Allergan stated that it […]

Read full story

Novartis announces that FDA brolucizumab injection approves to be noninferior to aflibercept in Phase III studies

Novartis AG (NYSE:NVS; SIX:NOVN) has announced that the U.S. Food and Drug Administration (FDA) has approved brolucizumab (“Beovu”) injection (also known as RTH258) for the treatment of wet age-related macular degeneration (AMD).  According to the company, the product is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept “and the ability […]

Read full story

A UK gene therapy company – Gyroscope Therapeutics Ltd – raises £50.4 million funding for retinal disease treatment

Gyroscope Therapeutics Ltd., based in Stevenage, UK, has announced the successful completion of a £50.4 million investment to advance clinical development of an investigational gene therapy treatment for dry age-related macular degeneration (dry-AMD).  The company is built on studies and scientific publications which link chronic local inflammation, activation of the complement system and AMD pathogenesis […]

Read full story

Related Market/Novel Tech News